Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company, announced plans to establish "American BNB Strategy," a subsidiary focused on cryptocurrency investments. The company aims to raise and deploy up to $500 million for strategic, long-term investments in BNB coin, the native token of the Binance ecosystem.
While maintaining its core focus on cancer therapeutics and diagnostics, Liminatus views this expansion into digital assets as crucial for long-term growth. The company plans to utilize Ceffu's custody infrastructure for institutional-grade security and is currently working with Digital Offering on the capital raise process, pending regulatory clearance and market conditions.
Liminatus Pharma (NASDAQ: LIMN), un'azienda biofarmaceutica in fase preclinica, ha annunciato l'intenzione di creare "American BNB Strategy," una controllata dedicata agli investimenti in criptovalute. L'azienda punta a raccogliere e investire fino a 500 milioni di dollari in investimenti strategici e a lungo termine nella moneta BNB, il token nativo dell'ecosistema Binance.
Mantenendo il suo focus principale su terapie e diagnostica oncologica, Liminatus considera questa espansione nel settore degli asset digitali fondamentale per una crescita duratura. L'azienda prevede di utilizzare l'infrastruttura di custodia di Ceffu per garantire sicurezza a livello istituzionale e sta collaborando con Digital Offering per il processo di raccolta fondi, in attesa delle autorizzazioni regolamentari e delle condizioni di mercato.
Liminatus Pharma (NASDAQ: LIMN), una compañía biofarmacéutica en etapa preclínica, anunció planes para establecer "American BNB Strategy," una subsidiaria enfocada en inversiones en criptomonedas. La empresa busca recaudar y desplegar hasta 500 millones de dólares para inversiones estratégicas y a largo plazo en BNB coin, el token nativo del ecosistema Binance.
Mientras mantiene su enfoque principal en terapias y diagnósticos contra el cáncer, Liminatus considera que esta expansión hacia activos digitales es crucial para el crecimiento a largo plazo. La compañía planea utilizar la infraestructura de custodia de Ceffu para seguridad de nivel institucional y actualmente trabaja con Digital Offering en el proceso de recaudación de capital, pendiente de la aprobación regulatoria y las condiciones del mercado.
Liminatus Pharma (NASDAQ: LIMN)는 전임상 단계의 생명공학 제약회사로, 암호화폐 투자에 중점을 둔 자회사 "American BNB Strategy" 설립 계획을 발표했습니다. 회사는 바이낸스 생태계의 기본 토큰인 BNB 코인에 대한 전략적이고 장기적인 투자를 위해 최대 5억 달러를 조달하고 운용하는 것을 목표로 하고 있습니다.
암 치료제 및 진단에 핵심 역량을 유지하면서도, Liminatus는 디지털 자산으로의 확장이 장기적인 성장에 필수적이라고 보고 있습니다. 회사는 기관급 보안을 위해 Ceffu의 수탁 인프라를 활용할 계획이며, 현재 규제 승인과 시장 상황을 기다리며 Digital Offering과 자본 조달 절차를 진행 중입니다.
Liminatus Pharma (NASDAQ : LIMN), une société biopharmaceutique en phase préclinique, a annoncé son projet de créer "American BNB Strategy," une filiale dédiée aux investissements en cryptomonnaies. L'entreprise vise à lever et déployer jusqu'à 500 millions de dollars pour des investissements stratégiques et à long terme dans le BNB coin, le jeton natif de l'écosystème Binance.
Tout en conservant son focus principal sur les thérapies et diagnostics contre le cancer, Liminatus considère cette expansion dans les actifs numériques comme essentielle pour une croissance durable. La société prévoit d'utiliser l'infrastructure de garde de Ceffu pour une sécurité de niveau institutionnel et travaille actuellement avec Digital Offering sur le processus de levée de fonds, en attente des autorisations réglementaires et des conditions du marché.
Liminatus Pharma (NASDAQ: LIMN), ein biopharmazeutisches Unternehmen in der präklinischen Phase, kündigte Pläne zur Gründung von "American BNB Strategy," einer Tochtergesellschaft, die sich auf Kryptowährungsinvestitionen spezialisiert. Das Unternehmen beabsichtigt, bis zu 500 Millionen US-Dollar für strategische, langfristige Investitionen in die BNB-Münze, den nativen Token des Binance-Ökosystems, zu beschaffen und einzusetzen.
Während der Fokus weiterhin auf Krebsbehandlungen und Diagnostik liegt, sieht Liminatus diese Expansion in digitale Vermögenswerte als entscheidend für langfristiges Wachstum an. Das Unternehmen plant, die Verwahrungsinfrastruktur von Ceffu für institutionelle Sicherheit zu nutzen und arbeitet derzeit mit Digital Offering am Kapitalbeschaffungsprozess, vorbehaltlich regulatorischer Genehmigungen und der Marktbedingungen.
- Strategic expansion into cryptocurrency sector through dedicated subsidiary
- Planned fund size of up to $500 million for BNB coin investment
- Partnership with Ceffu for institutional-grade security infrastructure
- Potential for additional revenue streams through staking and Launchpool participation
- Significant deviation from core biopharmaceutical business model
- High risk exposure to volatile cryptocurrency markets
- Capital raise requirements may lead to potential dilution
- Regulatory uncertainties surrounding cryptocurrency investments
Insights
Liminatus Pharma's pivot to crypto with $500M BNB investment marks unusual diversification for a preclinical biotech, raising significant strategic questions.
Liminatus Pharma (NASDAQ: LIMN) has announced a substantial strategic pivot with plans to establish "American BNB Strategy," a subsidiary aimed at investing up to
This move is particularly unusual given Liminatus's current status as a preclinical-stage biopharmaceutical company. Typically, companies at this early development stage are intensely focused on advancing their therapeutic candidates through clinical trials - a process that itself requires substantial capital investment. The decision to potentially divert significant resources toward cryptocurrency holdings represents a highly unconventional strategy that deviates sharply from industry norms.
While the company states it "remains fully committed" to its core cancer therapeutics business, the scale of the proposed crypto initiative (
The announcement indicates the capital will be raised through a planned fund rather than redirecting existing resources. However, this still represents a significant commitment of organizational focus and raises questions about management's strategic priorities. Additionally, the plan remains subject to board approval, regulatory clearance, and market conditions, indicating several hurdles remain before implementation.
This unusual strategy appears to represent a high-risk pivot that substantially alters the company's risk profile. Investors who purchased shares based on Liminatus's pharmaceutical development potential now face exposure to cryptocurrency market volatility - a fundamentally different risk proposition than traditional biotech investment.
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to
LA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced plans for a strategic expansion into the cryptocurrency and blockchain sector.
The company intends to establish a dedicated subsidiary, named “American BNB Strategy,” to lead its digital asset investment and management initiatives. Through this planned vehicle, Liminatus aims to raise and deploy up to
This announcement follows an internal review of blockchain-integrated financial strategies conducted over the past several weeks.
Liminatus emphasized that while it remains fully committed to its core business — advancing cancer therapeutics and developing pancreatic cancer diagnostics — the company believes that expanding into the digital asset space is a necessary step to support long-term growth and enhance shareholder value.
The proposed subsidiary, “American BNB Strategy,” is expected to focus on the strategic and structured acquisition and long-term holding of BNB Coin, utilizing capital raised through the planned fund. The company clarified that this is not a short-term speculative initiative, but rather a value driven strategy based on the long-term growth potential and strength of the BNB ecosystem.
Chris Kim, CEO of Liminatus, stated that BNB Coin was selected over numerous digital assets due to its robust technology, global user base, value generating features such as Launchpool participation and staking models, and the ongoing expansion of the BNB Chain.
He added that Liminatus expects to utilize custody infrastructure provided by Ceffu, an affiliated entity within the BNB ecosystem, to ensure institutional grade security and operational integrity. The company believes this approach will enable a secure and compliant entry into the digital asset sector and support its long-term capital strategy.
Establishing a dedicated subsidiary for large-scale cryptocurrency investment and designating a specific blockchain token as a core treasury asset is a rare move for a traditional biopharmaceutical company. Liminatus believes this bold initiative could set a precedent for how other Nasdaq listed companies approach participation in the digital asset economy.
As of the date of this announcement, Liminatus is actively engaged in a capital raise process in collaboration with placement agent Digital Offering, and the Board is in the process of finalizing its review and approval. The initiative remains subject to regulatory clearance and prevailing market conditions.
About Liminatus Pharma, Inc.
Liminatus is a preclinical-stage biopharmaceutical company developing immunotherapies for patients with cancer. The Company is advancing a pipeline of novel therapies targeting cancer antigens and tumor-specific immune responses. Liminatus is also committed to responsible innovation in capital strategy to support its long-term scientific and operational objectives.
Forward-Looking Statements
Certain statements in this press release constitute forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding management’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects. Future developments affecting Liminatus may not be those that Liminatus has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of Liminatus), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Liminatus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
In addition, statements that “we believe” and similar statements reflect beliefs and opinions on the relevant subject. These statements are based upon information available to Liminatus as of the date of this press release, and while Liminatus believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that Liminatus has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements as predictions of future results. Liminatus’s actual future results may be materially different from what it expects. Liminatus qualifies all forward-looking statements by these cautionary statements.
Investor Relations Contact: Company Contact: Liminatus Pharma, Inc. info@liminatuspharma.com
FAQ
What is Liminatus Pharma's (LIMN) new cryptocurrency initiative?
How much does Liminatus Pharma (LIMN) plan to invest in BNB coin?
Will Liminatus Pharma (LIMN) continue its cancer research business?
Who will provide custody services for Liminatus Pharma's (LIMN) crypto investments?
What is the current status of Liminatus Pharma's (LIMN) crypto initiative?
